Viking Therapeutics Raises $575 Million for Obesity Drug Pipeline

The equity offering gives Viking a substantial cash runway to advance VK2735 through late-stage trials, placing its commercial timeline in sharper focus ahead of a competitive obesity drug market.

Viking Therapeutics completed a $575 million equity raise on October 18, 2026, according to Motley Fool, making it one of the larger single capital raises by a mid-stage biotech company focused on obesity treatments in recent memory. The proceeds are designated for clinical trial funding, pipeline development, and commercial preparation for any regulatory approvals tied to its lead asset, VK2735.

VK2735 is Viking's dual GIP and GLP-1 receptor agonist candidate. The company has advanced VK2735 through Phase 2 trials in both subcutaneous and oral formulations. Phase 3 trials, which are required for a New Drug Application submission to the Food and Drug Administration, are the next milestone. The $575 million raise is intended to fund that next stage, according to the Motley Fool report.

The capital raise was structured as a public equity offering. The specific share count, offer price per share, and degree of dilution to existing shareholders were not detailed in the available source material. Those figures would be disclosed in the prospectus supplement filed with the Securities and Exchange Commission at the time of the offering, which would be publicly accessible through the SEC's EDGAR database.

Viking Therapeutics trades on the Nasdaq under the ticker VKTX. The company has no approved products and no product revenue as of its most recent quarterly filings. Its financial position before this raise consisted primarily of cash and investments from prior equity offerings, a structure typical of pre-commercial biotechs.

The obesity therapeutics market has drawn substantial investment attention following the commercial success of GLP-1 drugs developed by Novo Nordisk and Eli Lilly. Novo Nordisk's semaglutide, sold as Wegovy for obesity, generated approximately $6.7 billion in sales in the first nine months of 2025, according to the company's published earnings. Eli Lilly's tirzepatide, sold as Zepbound, recorded approximately $4.9 billion in obesity and diabetes combined revenues over a similar period. These figures establish the commercial scale that later entrants, including Viking, are targeting.

Viking's subcutaneous VK2735 posted a mean placebo-adjusted weight reduction of approximately 14.7 percent over 13 weeks in its Phase 2 study, results the company disclosed in a press release earlier in 2025. The oral formulation is at an earlier clinical stage. Phase 3 data, not Phase 2 results, are the regulatory standard for FDA approval.

The timing of the capital raise coincides with a broader period of equity market volatility. U.S. Stock futures rebounded on October 18, 2026, following a technology-led selloff on the prior Friday, according to Bloomberg. Biotech equities, which are sensitive to risk sentiment, can face pricing pressure during broad market downturns, which can in turn affect the terms at which companies access equity capital. The degree to which market conditions affected Viking's offering terms is not stated in available source material.

For existing shareholders, equity raises of this size typically result in dilution, meaning each existing share represents a smaller ownership percentage of the company after new shares are issued. The economic effect depends on the price at which new shares were sold relative to the market price at the time of pricing. Those details are disclosed in SEC filings.

For potential future shareholders and drug plan administrators, the central question is whether Phase 3 trial results for VK2735 will replicate or exceed Phase 2 outcomes, and whether the FDA will find the efficacy and safety profile sufficient for approval. Neither outcome is determinable from current data.

Viking's $575 million raise positions the company to reach late-stage trial readouts without requiring additional near-term dilution, assuming spending rates remain consistent with disclosed plans. What those spending rates are in annualized terms was not detailed in available source material, and that figure would be found in the company's most recent quarterly report filed with the SEC.